drugset / Trial / NCT01664676
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Phase 4
Completed
11 enrolled
University of Aarhus
Novo Nordisk A/S · collabUniversity of Copenhagen · collab
RandomizedCrossoverDouble-blindTreatment
Summary
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans. This study will investigate the short-term effect of liraglutide (GLP-1 analogue) on the kidneys in type 2 diabetic patients. Impact on basic kidney physiological will be determined and kidney injury markers will be measured as surrogate parameters of kidney protection.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.2 mg | Subcutaneous |